The $7M injection and Nasdaq compliance are near-term positives, but the liquidity covenant waiver and flat ~$10.5M quarterly revenue signal persistent operational challenges. Monitor the October 1, 2026 deadline for the stricter $3M minimum liquidity covenant and any updates on the CGM+ and Trinovium strategic initiatives for signs of revenue inflection.
Price Chart
Executive Summary
Trinity Biotech secured a $7.0M investment from Perceptive Advisors ($2.5M new debt, $4.5M capitalized interest) via a credit agreement amendment that also waives a liquidity covenant breach for June-August 2026. The company regained Nasdaq minimum bid price compliance on August 7, 2026. Preliminary Q2 2026 revenue was ~$10.5M, flat QoQ, as the company continues its operational transformation. The new funding provides near-term liquidity but the liquidity covenant waiver and flat revenue highlight ongoing financial strain.
Key Facts
- Perceptive Advisors provided ~$7.0M total investment: ~$2.5M new debt (Tranche F Term Loan) and ~$4.5M capitalized interest.
- Lenders waived the Minimum Liquidity Covenant ($1M minimum cash) for June, July, and August 2026 due to non-compliance.
- The Minimum Liquidity Covenant increases to $3M starting October 1, 2026.
- Regained compliance with Nasdaq minimum bid price ($1.00) as of August 7, 2026.
- Preliminary Q2 2026 revenue was ~$10.5M, broadly consistent with Q1 2026.
- The amendment adds a new Tranche F Term Loan commitment of $2.5M from Perceptive.
- As of August 13, 2026, the company had 487,879,340 ordinary shares outstanding; each ADS represents 600 ordinary shares.
Financial Impact
Total new liquidity injection of approximately $7.0 million, comprising $2.5 million in new debt and $4.5 million in capitalized interest. The company had been in breach of its $1M minimum liquidity covenant.
Risk Factors
- Liquidity covenant increases to $3M on October 1, 2026, which may require further financing or asset sales.
- Revenue remains flat at ~$10.5M/quarter, indicating the operational transformation has not yet driven growth.
- High debt load with PIK interest and a January 2027 maturity date creates refinancing risk.
- Heavy reliance on a single lender (Perceptive) for both debt and equity support.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001554855-26-001851 |
| Exhibit: ex991_1.htm | 0001554855-26-001851 |
| Document: MainDocument.htm | 0001554855-26-001851 |
| Document: 0001554855-26-001851-index-headers.html | 0001554855-26-001851 |
| Document: 0001554855-26-001851-index.html | 0001554855-26-001851 |
| Document: 0001554855-26-001851.txt | 0001554855-26-001851 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 6-K | $5.77 | awaiting T+60 | — | $7.11 (+23.22%) |
Sep 9, 2026 6w ago | 6-K | $8.00 | awaiting T+60 | — | $7.11 (−11.12%) |
Sep 2, 2026 7w ago | EFFECT | $9.60 | awaiting T+60 | — | $7.11 (−25.94%) |
Aug 28, 2026 8w ago | 6-K | $9.87 | awaiting T+60 | — | $7.11 (+27.96%) |
Aug 21, 2026 9w ago | F-1/A | $10.60 | awaiting T+60 | — | $7.11 (−32.92%) |
Aug 17, 2026 10w ago | 6-K | $11.17 | awaiting T+60 | — | $7.11 (−36.35%) |
Aug 14, 2026 10w ago | 6-K | $11.67 | awaiting T+60 | — | $7.11 (−39.07%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.11 (+2244.21%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.11 (+2244.21%) |
Jul 2, 2026 16w ago | 6-K | $0.3765 $0.2240 | ▼ −40.50% | ▼ −43.30% | $7.11 (+1788.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers